Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines

Q Dai, YH Ling, M Lia, YY Zou, G Kroog, KK Iwata… - Clinical Cancer …, 2005 - AACR
… The IC 50 values of erlotinib in these resistant cell lines are 3- to 20-fold lower than their …
Erlotinib resistance indices remained close to 1 in other resistant sublines A2780/CDDP, KB/…

[HTML][HTML] Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib

K Suda, K Tomizawa, M Fujii, H Murakami… - Journal of thoracic …, 2011 - Elsevier
… We developed resistant cells (HCC4006ER) from erlotinib-sensitive HCC4006 cells …
concentrations of erlotinib. Acquired resistance mechanisms of HCC4006ER cells were analyzed. …

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma

K Politi, PD Fan, R Shen… - Disease models & …, 2010 - journals.biologists.com
… and erlotinib; however, drug-resistant tumors eventually emerge. In 60% of cases, resistant
… Here, we describe the establishment of erlotinib resistance in lung tumors, which were …

Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib

KM Giles, FC Kalinowski, PA Candy, MR Epis… - Molecular cancer …, 2013 - AACR
erlotinib resistance. … erlotinib resistance in HNC and suggest that therapeutic inhibition of
Axl by small molecule drugs or specific miRNAs might overcome anti-EGFR therapy resistance

A novel epidermal growth factor receptor inhibitor promotes apoptosis in non–small cell lung cancer cells resistant to erlotinib

T de La Motte Rouge, L Galluzzi, KA Olaussen… - Cancer research, 2007 - AACR
growth factor receptor (VEGFR) inhibitor, BMS-690514, that exerts antiproliferative and
proapoptotic effects on NSCLC cell lines, in particular on cells that are resistant to erlotinib due to …

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

DB Costa, KSH Nguyen, BC Cho, LV Sequist… - Clinical cancer …, 2008 - AACR
… Other oncogenes, such as the insulin-like growth factor-I receptor, may also play a role in
resistance to EGFR TKIs in non-EGFR mutated cells (48). Despite a rapidly growing …

… of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib

F Morgillo, JK Woo, ES Kim, WK Hong, HY Lee - Cancer research, 2006 - AACR
… -like growth factor-1 receptor (IGF-IR) pathway is also implicated in the resistance of gefitinib
and … in the IGF-IR–mediated acquired resistance to erlotinib in NSCLC cells have not been …

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer

JA Engelman, PA Jänne - Clinical Cancer Research, 2008 - AACR
… It will be important to continue to study preclinical models and tumors from NSCLC patients
that have developed gefitinib/erlotinib resistance to uncover novel resistance mechanisms. …

[HTML][HTML] Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant …

M Serizawa, T Takahashi, N Yamamoto… - Journal of Thoracic …, 2013 - Elsevier
Erlotinib-resistant PC-9ER cells were generated from PC-9 NSCLC cells, which harbor an …
growth factor beta (TGF-β) pathway in cell motility, and tested the effects of erlotinib and TGF-β …

… endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance

GN Naumov, MB Nilsson, T Cascone, A Briggs… - Clinical Cancer …, 2009 - AACR
… were significantly more effective than erlotinib or gefitinib alone. Erlotinib resistance was …
Conclusion: These studies suggest that erlotinib resistance may be associated with a rise in …